What is a Clinical Study Report (CSR)?

Understand what a Clinical Study Report (CSR) is and why it’s critical for regulatory submission. Learn how the ICH E3 guideline shapes its structure and how expert medical writing ensures clarity, compliance, and approval-readiness.

clinical study report
medical device REGULATORY submissions
PHARMA & BIOLOGICS REGULATORY SUBMISSIONS
TECHNOLOGY
GLOBAL INSIGHTS
DEI IN REGULATORY WRITING
GLOBAL Medical Writing Team
August 7, 2025

ICH E3 Structure, Regulatory Purpose & Why Quality Writing Matters

Why Clinical Study Reports Matter

A Clinical Study Report (CSR) is one of the most important documents produced in the course of a clinical trial. Required for regulatory submissions such as INDs, BLAs, and NDAs in the US—and by global authorities including the EMA and Health Canada—a CSR presents a comprehensive account of the methods, conduct, and results of a clinical trial.

More than a summary, the CSR must interpret data clearly and objectively, demonstrate adherence to protocol, and provide enough detail to allow regulators to assess the trial's integrity and outcomes. Poorly written CSRs can lead to regulatory questions, delays, or even rejection. High-quality CSR writing is essential for getting your product one step closer to market approval.

What to Know About CSR Requirements

A CSR is required for any interventional clinical trial intended to support a regulatory submission. In the United States, CSRs support Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biologic License Applications (BLAs). In Europe and other regions, they are included in Marketing Authorization Applications (MAAs).

Regulatory agencies expect CSRs to follow the ICH E3 guideline, which outlines both the structure and level of detail expected in these reports. Compliance with ICH E3 is not optional—it ensures your document includes the context, methodology, and data interpretation regulators need to make informed decisions.

CSR Structure According to ICH E3

The ICH E3 guideline lays out a standardized format for CSRs that includes:

  • Title Page and Synopsis
    A concise summary of the trial, including objectives, design, results, and conclusions.
  • Table of Contents
    A detailed, organized listing of all included sections and appendices.
  • Ethics
    Documentation of ethics committee approvals and informed consent processes.
  • Study Administrative Structure
    Describes sponsors, investigators, contract research organizations (CROs), and other involved parties.
  • Introduction and Study Objectives
    Clearly defined study rationale and primary/secondary objectives.
  • Investigational Plan
    Detailed description of trial design, inclusion/exclusion criteria, dosing, and assessments.
  • Study Patients
    Demographic and baseline characteristics, patient disposition, protocol deviations.
  • Efficacy and Safety Results
    Comprehensive tables and narrative analyses of all relevant data.
  • Discussion and Conclusions
    An interpretation of the data, highlighting clinical relevance and limitations.
  • Appendices
    Includes the protocol, statistical analysis plan (SAP), sample case report forms, and more.

Adhering to this structure is essential for ensuring your submission is complete and review-ready.

Key Challenges in CSR Development

CSRs can be hundreds of pages long and require the integration of complex data from multiple sources. Common challenges include:

  • Aligning data from clinical, statistical, and safety teams
  • Ensuring consistency across text, tables, and listings
  • Communicating nuanced efficacy and safety results clearly
  • Managing iterative reviews from sponsors and stakeholders
  • Meeting tight regulatory timelines with minimal revisions

These challenges make it essential to work with experienced medical writers who understand regulatory expectations and have the skill to communicate your study's story with clarity and precision.

GLOBAL’s CSR Writing Services

GLOBAL’s regulatory writing team provides expert support for end-to-end CSR development. Whether you're preparing for a US FDA or EU submission, we help you meet ICH E3 requirements and tell a clear, compelling clinical story. Our services include:

  • Full CSR drafting and formatting
  • Gap analysis and document remediation
  • Integration of biostatistics and clinical data
  • Project management and stakeholder coordination
  • Response strategy for regulatory feedback

Strategic Compliance Starts with the Right Partner

A well-written CSR does more than document your trial—it builds trust with regulators. Our team of senior writers brings experience across therapeutic areas, trial phases, and global submissions. We help you reduce review cycles, improve quality, and stay on timeline.

Let us help you turn your trial results into a submission-ready report that speaks with clarity, accuracy, and confidence.

Contact us today to learn how our clinical writing team can accelerate your CSR development.

Sources

The Latest

GLOBAL Resources

IND vs. NDA: Understanding the Difference in FDA Submissions

For drug developers, FDA approval is a long and complex journey. Two of the most important milestones on this path are the Investigational New Drug (IND) application and the New Drug Application (NDA). While both are critical submissions, they serve very different purposes.

The FDA’s CMC Development and Readiness Pilot (CDRP) Program: What Sponsors Need to Know

In August 2023, the U.S. Food and Drug Administration (FDA) announced the launch of the Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program. This initiative is designed to help sponsors of certain accelerated development products better align their CMC strategies with the FDA early in the development process.

CMC Challenges in Cell & Gene Therapy: How to Avoid Regulatory Delays

In recent years, cell and gene therapies (CGTs) have transformed from scientific breakthroughs into commercial realities. These advanced modalities are redefining how we approach rare, genetic, and otherwise untreatable diseases—offering patients options that were once unimaginable. Yet, while the science is groundbreaking, the CMC (Chemistry, Manufacturing, and Controls) pathway remains one of the most significant obstacles to timely regulatory approval.

View More Resources from Global

Let's Get Started

GLOBAL provides trusted regulatory consulting , writing, and technology solutions to help manufacturers bring products to patients at a life saving pace. We’ll be with you every step of the way.

book a consultation
clinical study report